Currently out of the existing stock ratings of Gregory Fraser, 39 are a BUY (82.98%), 8 are a HOLD (17.02%).

Gregory Fraser

Work Performance Price Targets & Ratings Chart

Analyst Gregory Fraser, carries an average stock price target met ratio of 45.51% that have a potential upside of 42.18% achieved within 117 days. Previously, Gregory Fraser worked at TRUIST.

Gregory Fraser’s has documented 104 price targets and ratings displayed on 15 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ANIP, ANI Pharmaceuticals at 11-Aug-2025.

Wall Street Analyst Gregory Fraser

Analyst best performing recommendations are on EOLS (EVOLUS).
The best stock recommendation documented was for EOLS (EVOLUS) at 1/20/2022. The price target of $11 was fulfilled within 56 days with a profit of $5.46 (98.56%) receiving and performance score of 17.6.

Average potential price target upside

of $34.48 (50.01%) on NVCR (NOVOCURE LTD).
of $30.73 (68.12%) on XAIR (BEYOND AIR).
of $8.77 (15.27%) on ANIP (ANI PHARMACEUTICALS).

CRXT Clarus Therapeutics Holdings OSMT Osmotica Pharmaceuticals plc BDSI BioDelivery Sciences International NVCR Novocure Ltd ANIP ANI Pharmaceuticals CORT Corcept Therapeutics EOLS Evolus XAIR Beyond Air BHC Bausch Health Companies AERI Aerie Pharmaceuticals RVLP RVL Pharmaceuticals PLC AMRX Amneal Pharmaceuticals, Common Stock ARQT Arcutis Biotherapeutics BTMD biote Corp JAZZ Jazz Pharmaceuticals PLC

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score